Cyclosporin A as an Immunosuppressive Agent in Transplantation

  • R. Y. Calne


Cyclosporin A (CyA) is an immunosuppressive agent that has exciting major interest because of its potential. Borei discovered its in vitro and in vivo immunosuppressive properties in a screening program of fungal products. CyA is a cyclic peptide of 11 amino acids. CyA is highly soluble in alcohol and fat solvents but it is totally insoluble in aqueous solutions. Borel’s(1) demonstration of prolongation of skin graft survival between mice differing for the H2 locus led David White, in my department, to suggest investigation of CyA in an organ allograft model. Our initial studies(2) showed that the agent prolongs survival of heterotopic hearts in rats across an AGB incompatability barrier.


Renal Allograft Kidney Graft Kidney Allograft Heterotopic Pancreas Pancreas Allograft 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Borel JF: Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology 31:631–641, 1976.PubMedGoogle Scholar
  2. 2.
    Kostakis AJ, White DJG, Calne RY: Prolongation of the rat heart allograft survival by cyclosporin A. IRCS Med Sci 5:280, 1977.Google Scholar
  3. 3.
    Gordon MY, Singer JW: Selective effects of cyclosporin A on colony-forming lymphoid and myeloid cells in man. Nature 279:433–434, 1979.PubMedCrossRefGoogle Scholar
  4. 4.
    Calne RY, White DJG: Cyclosporin A—a powerful immunosuppressant in dogs with renal allografts. IRCS Med Sci 5:595, 1977.Google Scholar
  5. 5.
    Calne RY, White DJG, Rolles K, Smith DP, Herbertson BM: Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. Lancet 1:1183–1185, 1978.PubMedCrossRefGoogle Scholar
  6. 6.
    Green CJ, Allison AC: Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin A treatment. Lancet 1:1182–1183, 1978.PubMedCrossRefGoogle Scholar
  7. 7.
    Dunn DC, White DJG, Wade J: Survival of first and second kidney allografts after withdrawal of cyclosporin A therapy. IRCS Med Sci 6:464, 1978.Google Scholar
  8. 8.
    Jamieson SW, Burton NA, Bieber CP, Reitz BA, Oyer BE, Stinson EB, Shumway NE: Cardiac allograft survival in primates treated with cyclosporin A. Lancet 1:545, 1979.PubMedCrossRefGoogle Scholar
  9. 9.
    McMaster P, Procyshyn A, Calne RY, Valdes R, Rolles K, Smith D: Prolongation of canine pancreas allografts with cyclosporin A (a preliminary report). Transplant Proc 12:275–277, 1980.PubMedGoogle Scholar
  10. 10.
    Calne RY, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K: Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2:1323–1327, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Calne RY, Rolles K, White DJG, et al.: Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet 1:1033–1036, 1979.CrossRefGoogle Scholar
  12. 12.
    Dubernard JM, Traeger J, Meyra P, Touraine HL, Tranchant D, Blanc-Brunat A: A new method of preparation of segmental pancreatic grafts for transplantation trials in dogs and in man. Surgery 84:633–639, 1978.PubMedGoogle Scholar
  13. 13.
    Powles RL, Barrett AJ, Clink H, Kay HEM, Sloan J, McElwain TJ: Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet 2:1327–1331, 1978.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1985

Authors and Affiliations

  • R. Y. Calne
    • 1
  1. 1.Department of Surgery, School of MedicineCambridge UniversityCambridgeEngland

Personalised recommendations